EU OKs Astellas-Medivation's Xtandi capsules for prostate cancer

06/25/2013 | PharmaTimes (U.K.)

The European Commission granted Astellas Pharma and Medivation approval to market Xtandi, or enzalutamide, capsules as a treatment for metastatic castration-resistant prostate cancer after progression despite treatment with docetaxel. The drug was approved in the U.S. last year. The approval triggered the payment of a $15 million milestone fee from Astellas to Medivation.

View Full Article in:

PharmaTimes (U.K.)

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC
Sr. Principal OptoMechanical Engineer - 14000008M2
Abbott
San Jose, CA
Pharmacy Care Manager
National Association of Chain Drug Stores
Arlington, VA
Regional Director, Southeastern Region - State Affairs
America's Health Insurance Plans (AHIP)
Washington, DC
Sr. Principal Electrical Engineer - 14000008LR
Abbott
San Jose, CA